Author Archives for Client Pharma

Speciality Pharmaceuticals: Cost and Distribution

by

March 15, 2016 10:33 am | Leave your thoughts


pharma distribution solutions

Based on IMS health data, speciality pharmaceuticals are said to make up a quarter of prescription costs within the pharmaceutical market. This is purported to be the fastest growing costs within healthcare today. Used to treat specific cancers and rare diseases, they are termed ‘speciality’ due to their unusual or difficult process of delivery. IMS



Client Pharma at Arab Health 2016

by

February 8, 2016 12:44 pm | Leave your thoughts



Last month Client Pharma attended Arab Health 2016. Taking place in the International Convention and Exhibition Centre in Dubai, the healthcare exhibition is both the region’s largest and one of the biggest in the world. In its 41st edition, Arab Health is a unique platform for companies to unveil their latest innovations within the healthcare



The Price of Innovating Drugs

by

December 11, 2015 11:00 am | Leave your thoughts


Clinical trial supply services

The price of drugs and innovation into cures are inextricably linked. The subject of drug affordability and attainability is undoubtedly fraught with emotion. The high price that drugs are often sold for means that they are only available to those who have the capital to afford them. In countries where healthcare systems are government led



The Consequences of Counterfeit Drugs

by

November 3, 2015 4:26 pm | Leave your thoughts


pharma distribution solutions

Taking counterfeit medicines, either knowingly or unknowingly, can trigger dangerous side effects or cause serious health risks. The majority of counterfeit medicines are manufactured in developing countries such as Asia, Africa and Latin America as laws and government regulations are not as stringent in these countries. In some environments where counterfeit drugs are manufactured, the



Sustainable Logistics

by

May 12, 2015 11:33 am | Leave your thoughts



Logistics is the management of moving products from point A to point B, including prompt planning and organisation to carry out process effectively. At Client-Pharma, manage warehousing, inventory and order fulfilment to ensure our clients get the quality service we’ve promised. During logistics management, consideration must be taken regarding the environment and operation costs. The logistics industry



Supporting the Local Community

by

May 12, 2015 11:23 am | Leave your thoughts


Clinical trial supply services

Since Client-Pharma launched in 2013, we’ve been working in the heart of local communities to help improve people’s lives whether it’s through funding, training, sponsorship or fundraising. As big supporters of rugby, Client-Pharma jumped at the chance to sponsor our local rugby club, Barton under Needwood. Formed in 1990 with just one adult team playing



Client-Pharma returns to the Arab Health Exhibition

by

May 12, 2015 11:22 am | Leave your thoughts


pharma distribution solutions

As you may know, last year we attended the Arab Health exhibition in Dubai which aimed to showcase the latest products, services and achievements in the pharmaceutical world. Amongst the vast array of health professionals and varied services, Client-Pharma will be there networking and seeing just how far the industry has developed over the past



Risk mitigation and competitiveness

by

May 12, 2015 11:21 am | Leave your thoughts



UPS published its seventh Pain in the Chain survey last month, which revealed a correlation between a risk-informed approach and the rewards of global success. The survey polled 530 senior-level supply chain decision makers in the healthcare industry from the United States, Canada, Western Europe, Asia, and Latin America. Regulatory compliance, for the third consecutive



Global biosimilars market

by

May 12, 2015 11:21 am | Leave your thoughts


Clinical trial supply services

New research from the RAND Corporation research institute published this month, believes the introduction of biosimilar versions of complex biologic drugs to treat illnesses such as cancer and rheumatoid arthritis could cut US spending on biologics by $44 billion over the next decade. The global market for biosimilars is predicted to expand 20-fold in the



1 2 3